Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

The evolving role of alemtuzumab (Campath-1H) in renal transplantation.

Pham PT, Lipshutz GS, Pham PT, Kawahji J, Singer JS, Pham PC.

Drug Des Devel Ther. 2009 Sep 21;3:41-9.

2.

Alemtuzumab induction in deceased donor kidney transplantation.

Shin M, Song SH, Kim JM, Kwon CH, Joh JW, Lee SK, Kim SJ.

Transplant Proc. 2011 Jul-Aug;43(6):2365-78. doi: 10.1016/j.transproceed.2011.05.032.

PMID:
21839271
3.

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.

3C Study Collaborative Group, Haynes R, Harden P, Judge P, Blackwell L, Emberson J, Landray MJ, Baigent C, Friend PJ.

Lancet. 2014 Nov 8;384(9955):1684-90. doi: 10.1016/S0140-6736(14)61095-3. Epub 2014 Jul 28.

PMID:
25078310
4.

Alemtuzumab induction therapy in solid organ transplantation.

Friend PJ.

Transplant Res. 2013 Nov 20;2(Suppl 1):S5. doi: 10.1186/2047-1440-2-S1-S5. Epub 2013 Nov 20.

5.

Alemtuzumab (Campath-1H): a systematic review in organ transplantation.

Morris PJ, Russell NK.

Transplantation. 2006 May 27;81(10):1361-7. Review.

PMID:
16732169
6.

Alemtuzumab (Campath-1H) experience in kidney transplantation what we have learned; current practices; and scope for the future?

Gundroo A, Zachariah M, Singh N, Sharma R.

Curr Opin Organ Transplant. 2015 Dec;20(6):638-42. doi: 10.1097/MOT.0000000000000255. Review.

PMID:
26536426
7.

Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.

Flechner SM, Kobashigawa J, Klintmalm G.

Clin Transplant. 2008 Jan-Feb;22(1):1-15. doi: 10.1111/j.1399-0012.2007.00739.x. Review.

PMID:
18217899
8.

Use of the ImmuKnow assay to evaluate the effect of alemtuzumab-depleting induction therapy on cell-mediated immune function after renal transplantation.

Zhou H, Lin J, Chen S, Ma L, Qiu Z, Chen W, Zhang X, Zhang Y, Lin X.

Clin Exp Nephrol. 2013 Apr;17(2):304-9. doi: 10.1007/s10157-012-0688-1. Epub 2012 Oct 6.

PMID:
23053591
9.
10.

Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.

Kirsch BM, Haidinger M, Zeyda M, Böhmig GA, Tombinsky J, Mühlbacher F, Watschinger B, Hörl WH, Säemann MD.

Transpl Immunol. 2006 Nov;16(3-4):254-7. Epub 2006 Oct 4.

PMID:
17138063
11.

Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.

Morgan RD, O'Callaghan JM, Knight SR, Morris PJ.

Transplantation. 2012 Jun 27;93(12):1179-88. doi: 10.1097/TP.0b013e318257ad41. Review.

PMID:
22660659
12.

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, Cendales LK, Tadaki DK, Harlan DM, Swanson SJ.

Transplantation. 2003 Jul 15;76(1):120-9.

PMID:
12865797
14.

Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?

Höcker B, Tönshoff B.

Paediatr Drugs. 2011 Feb 1;13(1):49-69. doi: 10.2165/11538530-000000000-00000. Review.

PMID:
21162600
15.

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

Watson CJ, Bradley JA, Friend PJ, Firth J, Taylor CJ, Bradley JR, Smith KG, Thiru S, Jamieson NV, Hale G, Waldmann H, Calne R.

Am J Transplant. 2005 Jun;5(6):1347-53.

16.

Efficacy of alemtuzumab in organ transplantation: current clinical status.

Ciancio G, Burke GW, Warque ME, Miller J.

BioDrugs. 2006;20(2):85-92. Review. Erratum in: BioDrugs. 2007;21(2):77.

PMID:
16626166
17.
18.

Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview.

Höcker B, Tönshoff B.

Paediatr Drugs. 2009;11(6):381-96. doi: 10.2165/11316100-000000000-00000. Review.

PMID:
19877724
19.

Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.

Zanfi C, Lauro A, Cescon M, Dazzi A, Ercolani G, Grazi GL, Zanello M, Vivarelli M, Del Gaudio M, Ravaioli M, Cucchetti A, Vetrone G, Tuci F, Di Gioia P, Lazzarotto T, D'Errico A, Bagni A, Faenza S, Siniscalchi A, Pironi L, Pinna AD.

Transplant Proc. 2010 Jan-Feb;42(1):35-8. doi: 10.1016/j.transproceed.2009.12.019.

PMID:
20172276
20.

Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H).

Gallon L, Gagliardini E, Benigni A, Kaufman D, Waheed A, Noris M, Remuzzi G.

Clin J Am Soc Nephrol. 2006 May;1(3):539-45. Epub 2006 Apr 5.

Supplemental Content

Support Center